Market capitalization | $1.16b |
Enterprise Value | $947.43m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.08 |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-332.16m |
Free cash flow (TTM) Free cash flow | $-273.64m |
Cash position | $314.91m |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
6 Analysts have issued a Sana Biotechnology Inc forecast:
6 Analysts have issued a Sana Biotechnology Inc forecast:
Mar '24 |
+/-
%
|
||
Net profit | -107 -107 |
31%
31%
|
|
Depreciation and amortization | 3.75 3.75 |
51%
51%
|
|
Share compensation | 9.09 9.09 |
4%
4%
|
|
Operating cash flow | -66 -66 |
17%
17%
|
|
Investments | 16 16 |
627%
627%
|
|
Dividend paid | - - |
-
|
|
Free cash flow | -81 -81 |
0%
0%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses in identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 13, 2018 and is headquartered in Seattle, WA.
Head office | United States |
CEO | Steven Harr |
Employees | 328 |
Founded | 2018 |
Website | www.sana.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.